

In the claims:

1-112. (Cancelled)

113. (Currently amended) A method for inducing a therapeutic host immune response against a multi-epitopic *in vivo* antigen that does not elicit an effective host immune response, the method comprising:

contacting a multi-epitopic antigen present in a host's serum with a composition comprising a binding agent that specifically binds to a first epitope on the antigen, the binding agent present in the composition being non-radiolabeled, and allowing the binding agent to form a binding agent/antigen pair, whereby an effective host ~~immune~~-T cell response is elicited against a second epitope on the antigen in the binding agent/antigen pair.

114-116. (Cancelled)

117. (Currently amended) The method of ~~Claim-claim~~ 113, wherein the host immune response ~~comprises further comprising~~ a humoral immune response.

118. (Currently amended) The method of ~~Claim-claim~~ 113, wherein the multi-epitopic *in vivo* antigen is a soluble antigen.

119. (Currently amended) The method of ~~Claim-claim~~ 118, wherein the soluble antigen is a soluble tumor-associated antigen.

120. (Currently amended) The method of ~~Claim-claim~~ 118, wherein the soluble antigen is associated with a human ~~disease or condition~~cancer.

121-122. (Cancelled)

123. (Currently amended) The method of ~~Claim-claim~~ 113, wherein the binding agent is an antibody or a polypeptide including an antigen binding portion thereof.

124. (Cancelled)

125. (Currently amended) The method of ~~Claim-claim~~ 123, wherein the antibody is B43.13 which is produceable by a hybridoma having ATCC deposit number PTA-1883.

126-128. (Cancelled)

129. (Currently amended) The method of ~~Claim-claim~~ 113, wherein the antigen is CA125.

130. (Currently amended) The method of ~~Claim-claim~~ 129, wherein the level of CA125 in the host's serum is greater than 100U/ml.

131. (Currently amended) The method of ~~Claim-claim~~ 123, wherein the antigen is a soluble circulating antigen and the antigen is contacted with a sufficient amount of antibody to present all the circulating antigen to the immune system.

132. (Currently amended) The method of ~~Claim-claim~~ 113, wherein the antigen is contacted with binding agent in an amount of from 0.1 µg to 2 mg per kg of body weight of the host.

133. (Currently amended) The method of ~~Claim-claim~~ 132, wherein the antigen is contacted with binding agent in an amount from 1 µg to 200 µg per kg of body weight of the host.

134. (Currently amended) The method of ~~Claim-claim~~ 133, wherein allowing the binding agent to form a binding agent/antigen pair presents other epitopes on the antigen to the host's immune system.

135. (Currently amended) A method for inducing a therapeutic host immune response against a multi-epitopic *in vivo* antigen that does not elicit an effective host immune response, comprising administering to the host a composition comprising a ~~non-radiolabeled~~ binding agent that specifically binds to an epitope on the antigen, the binding agent present in the composition being non-radiolabeled, thereby forming a binding agent/antigen pair, whereby an effective ~~immune-host T cell~~ response is elicited against a second epitope of the antigen, the binding agent

being present in the composition in an amount of from 0.1 µg to 2 mg per kg of body weight of the host.

136. **(Cancelled)**

137. **(Currently amended)** The method of ~~Claim-claim~~ 135, wherein the antigen is a soluble antigen.

138. **(Currently amended)** The method of ~~Claim-claim~~ 135, wherein the antigen is a tumor antigen.

139. **(Currently amended)** The method of ~~Claim-claim~~ 137, wherein the antigen is a tumor antigen.

140. **(Cancelled)**

141. **(Currently amended)** The method of ~~Claim-claim~~ 113, wherein the composition comprising a binding agent further comprises one or more adjuvants, one or more carriers, one or more excipients, one or more stabilizers, one or more pharmaceutically acceptable carriers and/or physiologically acceptable saline.

142. **(Currently amended)** The method of ~~Claim-claim~~ 113, wherein contacting comprises administering by any immunologically suitable route.

143. **(Currently amended)** The method of ~~Claim-claim~~ 142, wherein administering by any immunologically suitable routes comprises intravenous, subcutaneous, intraperitoneal, intradermal, intramuscular, or intralymphatic routes.

144. **(Currently amended)** The method of ~~Claim-claim~~ 142, wherein administering by any immunologically suitable route comprises administering in solution, tablet, or aerosol form.

145-169. **(Cancelled)**

170. **(Currently amended)** The method of ~~Claim~~claim 135, wherein the composition comprising a binding agent further comprises one or more adjuvants, one or more carriers, one or more excipients, one or more stabilizers, one or more pharmaceutically acceptable carriers and/or physiologically acceptable saline.

171. **(Previously presented)** The method of claim 135, wherein the composition is administered by any immunologically suitable route.

172. **(Currently amended)** The method of ~~Claim~~claim 171, wherein administering by any immunologically suitable route comprises intravenous, subcutaneous, intraperitoneal, intradermal, intramuscular, or intralymphatic routes.

173. **(Currently amended)** The method of ~~Claim~~claim 171, wherein administering by any immunologically suitable route comprises administering in solution, tablet, or aerosol form.

174. **(Currently amended)** A method for inducing a therapeutic host immune response against a multi-epitopic *in vivo* antigen that does not elicit an effective host immune response, the method comprising contacting a multi-epitopic *in vivo* antigen present in a host's serum with a composition comprising a binding agent that specifically binds to an epitope on the antigen, the binding agent present in the composition being non-radiolabeled, and allowing the binding agent to form a binding agent/antigen complex, wherein the binding agent/antigen complex elicits an effective host ~~immune~~T cell response against a second epitope of the multi-epitopic *in vivo* antigen.

175. **(Currently amended)** The method of ~~Claim~~claim 174, wherein the effective host immune response is elicited against an epitope on the binding agent/antigen complex.

176-179. **Cancelled)**

180. **(Currently amended)** The method of ~~Claim~~claim 174, wherein the multi-epitopic *in vivo* antigen is a soluble antigen.

181. **(Currently amended)** The method of claim 180, wherein the soluble antigen is a soluble tumor-associated antigen.

182. **(Currently amended)** The method of ~~Claim-claim~~ 180, wherein the soluble antigen is associate with a human ~~disease or condition~~cancer.

183-184. **(Cancelled)**

185. **(Currently amended)** The method of ~~Claim-claim~~ 174, wherein the binding agent is an antibody or a polypeptide including an antigen binding portion thereof.

186. **(Cancelled)**

187. **(Currently amended)** The method of ~~Claim-claim~~ 174, wherein the binding agent is B43.13 which is produceable by a hybridoma having ATCC deposit number PTA-1883.

188-189. **(Cancelled)**

190. **(Currently amended)** The method of ~~Claim-claim~~ 185, wherein the antibody ~~comprises a native~~ is a non-human antibody.

191. **(Currently amended)** The method of ~~Claim-claim~~ 174, wherein the antigen is CA125.

192. **(Currently amended)** The method of ~~Claim-claim~~ 191, wherein the level of CA125 in the host's serum is greater than 100 U/ml.

193. **(Currently amended)** The method of ~~Claim-claim~~ 185, wherein the antigen is soluble circulating antigen and the antigen is contacted with a sufficient amount of antibody to present all the circulating antigen to the immune system.

194. **(Currently amended)** The method of ~~Claim-claim~~ 174, wherein the antigen is contacted with binding agent in an amount from 0.1 µg to 2 mg per kg of body weight of the host.

195. **(Currently amended)** The method of ~~Claim-claim~~ 194, wherein the antigen is contacted with binding agent in an amount from 1 μg to 200 μg per kg of body weight of the host.

196. **(Currently amended)** The method of ~~Claim-claim~~ 174, wherein allowing the binding agent to form a binding agent/antigen complex presents other epitopes on the antigen to the host's immune system.

197. **(Currently amended)** The method of ~~Claim-claim~~ 174, wherein the composition comprising a binding agent further comprises one or more adjuvants, one or more carriers, one or more excipients, one or more stabilizers, one or more pharmaceutically acceptable carriers and/or physiologically acceptable saline.

198. **(Currently amended)** The method of ~~Claim-claim~~ 174, wherein contacting comprises administering by any immunologically suitable route.

199. **(Currently amended)** The method of ~~Claim-claim~~ 198, wherein administering by any immunologically suitable route comprises intravenous, subcutaneous, intraperitoneal, intradermal, intramuscular, or intralymphatic routes.

200. **(Currently amended)** The method of ~~Claim-claim~~ 198, wherein administering by any immunologically suitable route comprises administering in solution, tablet, or aerosol form.

201. **(Currently amended)** A method for inducing a therapeutic host immune response against a multi-epitopic *in vivo* antigen that does not elicit an effective host immune response, comprising administering to the host a composition comprising a ~~non-radiolabeled~~ binding agent that specifically binds to an epitope on the antigen, the binding agent present in the composition being non-radiolabeled, thereby forming a binding agent/antigen complex, whereby an effective ~~immune-host~~ T cell response is elicited against the binding agent/antigen complex, the binding agent being present in the composition in an amount of from 0.1 μg to 2 mg per kg of body weight of the host.

202. **(Currently amended)** The method of ~~Claim~~claim 201, wherein the antigen is a soluble antigen.

203. **(Currently amended)** The method of ~~Claim~~claim 201, wherein the antigen is a tumor antigen.

204. **(Currently amended)** The method of ~~Claim~~claim 202, wherein the antigen is a tumor antigen.

205. **(Cancelled)**

206. **(Currently amended)** The method of ~~Claim~~claim 201, wherein the composition comprising a binding agent further comprises one or more adjuvants, one or more carriers, one or more excipients, one or more stabilizers, one or more pharmaceutically acceptable carriers and/or physiologically acceptable saline.

207. **(Previously presented)** The method of claim 201, wherein the composition is administered by any immunologically suitable route.

208. **(Currently amended)** The method of ~~Claim~~claim 207, wherein administering by any immunologically suitable route comprises intravenous, subcutaneous, intraperitoneal, intradermal, intramuscular, or intralymphatic routes.

209. **(Currently amended)** The method of ~~Claim~~claim 207, wherein administering by any immunologically suitable route comprises administering in solution, tablet, or aerosol form.

210-234. **(Cancelled)**

235. **(Previously presented)** The method according to any one of claims ~~[[115-121]]~~117-120, 129, 130, 132-135, 137-139, 141-144, 170-175, ~~[[177-183]]~~180, 182, 191-192, 194-204, or 206-209 wherein the binding agent is an antibody.

236. **(Previously presented)** The method of claim 235, wherein the antibody is a murine monoclonal antibody.

237. **(Previously presented)** The method of claim 235, wherein the antibody is an Abl antibody.

238. **(Previously presented)** The method according to any one of claims 123, 185, 190, or 193, wherein the antibody is an Abl antibody.

239. **(Previously presented)** The method according to claim 123 or 185 wherein the antibody or polypeptide including an antigen binding portion thereof is selected from the group consisting of a chimeric monoclonal antibody, a genetically engineered monoclonal antibody, a Fab fragment, a F(ab')₂ fragment, and a single chain fragment.

240. **(New)** The method according to claim 113, wherein the binding agent is administered to a host by any immunologically suitable route.

241. **(New)** The method according to claim 113, wherein the T cell response is directed against a host cell of the patient.

242. **(New)** The method according to claim 241, wherein the host cell of the patient is a cancerous cell.

243. **(New)** The method according to claim 113, wherein the antigen is a cell-surface-associated antigen with a carbohydrate moiety.

244. **(New)** The method according to claim 243, wherein the cell-surface associated antigen is a tumor-associated antigen.

245. **(New)** The method of claim 240, wherein administering by any immunologically suitable routes comprises intravenous, subcutaneous, intraperitoneal, intradermal, intramuscular, or intralymphatic routes.

246. (New) The method of claim 240, wherein administering by any immunologically suitable route comprises administering in solution, tablet, or aerosol form.
247. (New) The method according to claim 113, wherein the binding agent is photoactivated.
248. (New) The method according to claim 135, wherein the binding agent is photoactivated.
249. (New) The method according to claim 174, wherein the binding agent is photoactivated.
250. (New) The method according to claim 201, wherein the binding agent is photoactivated.
251. (New) The method of claim 135, further comprising a humoral immune response.
252. (New) The method of claim 174, further comprising a humoral immune response.
253. (New) The method of claim 201, further comprising a humoral immune response.
254. (New) The method of claim 113, wherein the binding agent is administered in a 2 mg dosage.
255. (New) The method of claim 135, wherein the binding agent is administered in a 2 mg dosage.
256. (New) The method of claim 174, wherein the binding agent is administered in a 2 mg dosage.
257. (New) The method of claim 201, wherein the binding agent is administered in a 2 mg dosage.